. 2012 Sep 11;24(2):433–441. doi: 10.1093/annonc/mds340

Table 2.

Associations between non-Hodgkin lymphoma, diffuse large B-cell lymphoma, follicular lymphoma and postmenopausal hormonal therapy among postmenopausal women

Hormone therapy^a	Controls	NHL	Pooled OR^b	95% CI	I² (%)	P_{heterogeneity}	DLBCL	Pooled OR^b	95% CI	I² (%)	P_{heterogeneity}	FL	Pooled OR^b	95% CI	I² (%)	P_{heterogeneity}
Hormone therapy	No. of studies = 9
Total^c	2731	2094					675					531
Never used	1584	1275	1	ref			439	1	ref			299	1	ref
Ever used	1109	772	0.79	0.69–0.90	0	0.50	217	0.66	0.54–0.80	0	0.45	218	0.82	0.66–1.01	0	0.55
Age first used (years)	No. of studies = 8^d
Total^c	2519	1987					637					501
Never used	1395	1176	1	ref			405	1	ref			273	1	ref
<45	244	188	0.88	0.71–1.10	0	0.64	51	0.72	0.51–1.02	0	0.60	57	1.01	0.72–1.43	0	0.49
45–49	259	193	0.84	0.68–1.05	0	0.57	59	0.77	0.55–1.06	0	0.85	54	0.86	0.62–1.21	0	0.91
50–54	322	209	0.74	0.61–0.91	0	0.59	54	0.58	0.42–0.80	0	0.93	63	0.82	0.60–1.12	0	0.70
≥55	235	156	0.78	0.62–0.98	0	0.65	43	0.70	0.48–1.01	0	0.62	35	0.73	0.45–1.18	22	0.25
Trend			0.92	0.88–0.96	0	0.44		0.87	0.81–0.94	0	0.50		0.92	0.85–0.99	8	0.37
Years used	No. of studies = 9
Total^c	2731	2094					675					531
Never used	1584	1275	1	ref			439	1	ref			299	1	ref
<2	242	160	0.78	0.62–0.98	0	0.81	53	0.73	0.52–1.02	0	0.46	39	0.78	0.52–1.16	4	0.40
2 to <5	231	180	0.90	0.72–1.13	0	0.69	51	0.81	0.57–1.14	0	0.72	52	0.97	0.69–1.37	0	0.87
5 to <10	238	152	0.72	0.57–0.91	0	0.80	37	0.59	0.40–0.86	0	0.44	41	0.73	0.51–1.06	0	0.61
≥10	363	258	0.86	0.65–1.13	35	0.14	72	0.79	0.52–1.20	32	0.16	79	0.99	0.73–1.34	0	0.53
Trend			0.94	0.90–0.98	7	0.38		0.91	0.83–1.00	35	0.14		0.98	0.90–1.06	24	0.23
Years since last used	No. of studies = 6^d
Total^c	2035	1647					552					418
Never used	1237	1050	1	ref			368	1	ref			246	1	ref
>5	153	128	1.00	0.77–1.30	0	0.47	40	0.88	0.60–1.30	0	0.67	26	0.76	0.48–1.19	0	0.99
≤5	89	80	0.97	0.69–1.35	0	0.58	23	0.84	0.50–1.40	0	0.47	25	1.05	0.64–1.71	0	0.85
Current	504	331	0.70	0.54–0.90	40	0.14	100	0.57	0.44–0.74	0	0.54	103	0.76	0.58–0.99	0	0.46
Trend			0.89	0.82–0.97	44	0.11		0.83	0.77–0.91	0	0.49		0.92	0.84–1.00	0	0.46

^aHormone therapy among postmenopausal women where menopause was defined as the reporting of periods that stopped naturally or due to a bilateral oopherectomy, or, in the absence of these data, women aged ≥55 years were considered postmenopausal.

^bPooled ORs adjusted for age and ethnicity were estimated in meta-analysis using a random-effects model; pooled ORs and CIs were similar from a fixed-effects model where the amount of between-study variation in risk (I²) was low.

^cFrequencies do not sum to the total due to missing values.

^dHERPACC2 did not collect age when hormone therapy was first used, and Mayo, Los Angeles and HERPACC2 did not collect age when hormone therapy was last used.

NHL, non-Hodgkin lymphoma; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma.